Washington (AFP)
The US Medicines Agency, the FDA, is expected to fully approve Pfizer and BioNtech's vaccine against Covid-19 in September, the New York Times said on Tuesday.
According to the newspaper, which quotes sources familiar with the matter, "the unofficial date" on which the anti-Covid vaccine should get the full green light from the FDA "is around Labor Day (editor's note: September 6) or earlier".
Pfizer delivers its vaccines under a temporary emergency authorization granted on December 11, 2020.
Last week, the FDA said in a statement that the approval process for the anti-Covid vaccine was "among the agency's highest priorities" and that it expected to render its decision well before the end of the deadline.
Full serum approval could boost confidence and push more Americans to get vaccinated at a time when the highly contagious Delta virus is pushing up the number of cases in the country.
Some 192 million Americans have received at least one dose of the vaccine, or 58% of the population or 70% of adults.
At the same time, as of July 27, according to figures from the Centers for Disease Prevention and Control (CDC), Covid-19 cases have risen to 66,000 per day, six times more than in June.
Moderna, the other widely used vaccine, also authorized under an emergency regime, also applied, but later, applied for full approval.
Johnson and Johnson and his one-dose vaccine has yet to request it, according to the newspaper.
© 2021 AFP